Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases

Sugaya,Akinori; Ishiguro,Shingo; Mitsuhashi,Shoichi; Abe,Masahiro; Hashimoto,Ikuta; Kaburagi,Takayuki; Kojima,Hiroshi

doi:10.3892/mco.2016.1113

February-2017 Volume 6 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2017 Volume 6 Issue 2

Full Size Image

Article

Interstitial lung disease associated with trastuzumab monotherapy: A report of 3 cases

Authors:
- Akinori Sugaya
- Shingo Ishiguro
- Shoichi Mitsuhashi
- Masahiro Abe
- Ikuta Hashimoto
- Takayuki Kaburagi
- Hiroshi Kojima
View Affiliations / Copyright

Affiliations: Department of Clinical Oncology, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan, Department of Pulmonary Medicine, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki 309‑1793, Japan
Pages: 229-232
|
Published online on: December 19, 2016

https://doi.org/10.3892/mco.2016.1113
Expand metrics +

Abstract

We herein report 3 cases of female patients with breast cancer who developed interstitial lung disease (ILD) during trastuzumab monotherapy in an adjuvant setting. Prior chemotherapy included 4 cycles of epirubicin and cyclophosphamide in patients 1 and 2, and 4 cycles of docetaxel, cyclophosphamide and trastuzumab in patient 3. Patient 1 presented with a cough and fever after the fourth cycle of trastuzumab. Patient 2 experienced rapid deterioration of oxygen saturation without subjective symptoms within 3 h of the first administration of trastuzumab. Patient 3 was unexpectedly diagnosed with organizing pneumonia in a scheduled computed tomography (CT) scan after the first course of trastuzumab. Based on clinical data, such as decreased PaO2 level, increased serum levels of KL‑6 and/or lactate dehydrogenase, and findings on chest CT, these patients were diagnosed with drug‑induced ILD. Considering the clinical course, trastuzumab was incriminated as the cause of ILD, particularly in patients 1 and 2. All 3 patients improved due to the timely diagnosis, discontinuation of trastuzumab and immediate administration of corticosteroid therapy. Although ILD is a rare adverse event associated with trastuzumab, it may cause rapid deterioration without preceding symptoms. Close observation and early diagnosis are required to avoid an unfavorable outcome.

View Figures

View References

1	Slamon DJ, LeylandJones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
2	Piccart-Gebhart MJ, Procter M, LeylandJones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
3	Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI
4	Goldhirsch A, Gelber RD, PiccartGebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, et al: 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial. Lancet. 382:1021–1028. 2013. View Article : Google Scholar : PubMed/NCBI
5	Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
6	Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
7	Vahid B and Marik PE: Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 133:528–538. 2008. View Article : Google Scholar : PubMed/NCBI
8	Abulkhair O and El Melouk W: Delayed paclitaxel- trastuzumab-induced interstitial pneumonitis in breast cancer. Case Rep Oncol. 4:186–191. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kuip E and Muller E: Fatal pneumonitis after treatment with docetaxel and trastuzumab. Neth J Med. 67:237–239. 2009.PubMed/NCBI
10	Radzikowska E, Szczepulska E, Chabowski M and Bestry I: Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J. 21:552–555. 2003. View Article : Google Scholar : PubMed/NCBI
11	Vahid B and Mehrotra A: Trastuzumab (Herceptin)-associated lung injury. Respirology. 11:655–658. 2006. View Article : Google Scholar : PubMed/NCBI
12	Bettini AC, Tondini C, Poletti P, Caremoli ER, Guerra U and Labianca R: A case of interstitial pneumonitis associated with Guillain-Barré syndrome during administration of adjuvant trastuzumab. Tumori. 94:737–741. 2008.PubMed/NCBI
13	Pepels MJ, Boomars KA, van Kimmenade R and Hupperets PS: Life-threatening interstitial lung disease associated with trastuzumab: Case report. Breast Cancer Res Treat. 113:609–612. 2009. View Article : Google Scholar : PubMed/NCBI